Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Identifieur interne : 000016 ( Main/Exploration ); précédent : 000015; suivant : 000017Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Auteurs : RBID : pubmed:24396030English descriptors
- KwdEn :
- Aged, Antibodies, Monoclonal (pharmacokinetics), Antigens, CD31 (metabolism), Carcinoma, Renal Cell (drug therapy), Carcinoma, Renal Cell (radionuclide imaging), Drug Synergism, Female, Humans, Immunohistochemistry, Indium Radioisotopes (pharmacokinetics), Intervention Studies, Kidney Neoplasms (drug therapy), Kidney Neoplasms (radionuclide imaging), Male, Middle Aged, Neoadjuvant Therapy (methods), Niacinamide (analogs & derivatives), Niacinamide (therapeutic use), Phenylurea Compounds (therapeutic use), Protein-Tyrosine Kinases (antagonists & inhibitors), Radionuclide Imaging.
- MESH :
- chemical , analogs & derivatives : Niacinamide.
- chemical , antagonists & inhibitors : Protein-Tyrosine Kinases.
- chemical , metabolism : Antigens, CD31.
- chemical , pharmacokinetics : Antibodies, Monoclonal, Indium Radioisotopes.
- drug therapy : Carcinoma, Renal Cell, Kidney Neoplasms.
- methods : Neoadjuvant Therapy.
- radionuclide imaging : Carcinoma, Renal Cell, Kidney Neoplasms.
- chemical , therapeutic use : Niacinamide, Phenylurea Compounds.
- Aged, Drug Synergism, Female, Humans, Immunohistochemistry, Intervention Studies, Male, Middle Aged, Radionuclide Imaging.
Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the chronic nature of the treatment, and the side effects are clear disadvantages. An interesting new approach in the treatment of clear cell RCC is antibody-mediated therapy with the chimeric anti-carbonic anhydrase IX (CAIX) antibody girentuximab (cG250). As the results of several girentuximab trials become available, the question arises of whether TKI treatment can be combined with girentuximab-based therapy. In this study, we assessed the effect of the widely used TKI sorafenib on the tumor-targeting potential of (111)In-labeled girentuximab.
DOI: 10.2967/jnumed.113.131110
PubMed: 24396030
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.</title><author><name sortKey="Muselaers, Constantijn H J" uniqKey="Muselaers C">Constantijn H J Muselaers</name><affiliation wicri:level="1"><nlm:affiliation>Radboud university medical center, Department of Urology, Nijmegen, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Radboud university medical center, Department of Urology, Nijmegen</wicri:regionArea></affiliation></author><author><name sortKey="Stillebroer, Alexander B" uniqKey="Stillebroer A">Alexander B Stillebroer</name></author><author><name sortKey="Desar, Ingrid M E" uniqKey="Desar I">Ingrid M E Desar</name></author><author><name sortKey="Boers Sonderen, Marye J" uniqKey="Boers Sonderen M">Marye J Boers-Sonderen</name></author><author><name sortKey="Van Herpen, Carla M L" uniqKey="Van Herpen C">Carla M L van Herpen</name></author><author><name sortKey="De Weijert, Mirjam C A" uniqKey="De Weijert M">Mirjam C A de Weijert</name></author><author><name sortKey="Langenhuijsen, Johan F" uniqKey="Langenhuijsen J">Johan F Langenhuijsen</name></author><author><name sortKey="Oosterwijk, Egbert" uniqKey="Oosterwijk E">Egbert Oosterwijk</name></author><author><name sortKey="Leenders, William P J" uniqKey="Leenders W">William P J Leenders</name></author><author><name sortKey="Boerman, Otto C" uniqKey="Boerman O">Otto C Boerman</name></author><author><name sortKey="Mulders, Peter F A" uniqKey="Mulders P">Peter F A Mulders</name></author><author><name sortKey="Oyen, Wim J G" uniqKey="Oyen W">Wim J G Oyen</name></author></titleStmt><publicationStmt><date when="2014">2014</date><idno type="RBID">pubmed:24396030</idno><idno type="pmid">24396030</idno><idno type="doi">10.2967/jnumed.113.131110</idno><idno type="wicri:Area/Main/Corpus">000225</idno><idno type="wicri:Area/Main/Curation">000225</idno><idno type="wicri:Area/Main/Exploration">000016</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Antigens, CD31 (metabolism)</term><term>Carcinoma, Renal Cell (drug therapy)</term><term>Carcinoma, Renal Cell (radionuclide imaging)</term><term>Drug Synergism</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Indium Radioisotopes (pharmacokinetics)</term><term>Intervention Studies</term><term>Kidney Neoplasms (drug therapy)</term><term>Kidney Neoplasms (radionuclide imaging)</term><term>Male</term><term>Middle Aged</term><term>Neoadjuvant Therapy (methods)</term><term>Niacinamide (analogs & derivatives)</term><term>Niacinamide (therapeutic use)</term><term>Phenylurea Compounds (therapeutic use)</term><term>Protein-Tyrosine Kinases (antagonists & inhibitors)</term><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Niacinamide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Protein-Tyrosine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD31</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Neoadjuvant Therapy</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Renal Cell</term><term>Kidney Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Niacinamide</term><term>Phenylurea Compounds</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Synergism</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Intervention Studies</term><term>Male</term><term>Middle Aged</term><term>Radionuclide Imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the chronic nature of the treatment, and the side effects are clear disadvantages. An interesting new approach in the treatment of clear cell RCC is antibody-mediated therapy with the chimeric anti-carbonic anhydrase IX (CAIX) antibody girentuximab (cG250). As the results of several girentuximab trials become available, the question arises of whether TKI treatment can be combined with girentuximab-based therapy. In this study, we assessed the effect of the widely used TKI sorafenib on the tumor-targeting potential of (111)In-labeled girentuximab.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24396030</PMID><DateCreated><Year>2014</Year><Month>02</Month><Day>04</Day></DateCreated><DateCompleted><Year>2014</Year><Month>04</Month><Day>08</Day></DateCompleted><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</Title><ISOAbbreviation>J. Nucl. Med.</ISOAbbreviation></Journal><ArticleTitle>Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.</ArticleTitle><Pagination><MedlinePgn>242-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2967/jnumed.113.131110</ELocationID><Abstract><AbstractText Label="UNLABELLED">Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC). Although TKIs have demonstrated good clinical efficacy, the lack of complete responses, the chronic nature of the treatment, and the side effects are clear disadvantages. An interesting new approach in the treatment of clear cell RCC is antibody-mediated therapy with the chimeric anti-carbonic anhydrase IX (CAIX) antibody girentuximab (cG250). As the results of several girentuximab trials become available, the question arises of whether TKI treatment can be combined with girentuximab-based therapy. In this study, we assessed the effect of the widely used TKI sorafenib on the tumor-targeting potential of (111)In-labeled girentuximab.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">(111)In-girentuximab imaging was performed on 15 patients suspected of having a renal malignancy, with surgery being part of their treatment plan. Of these, 10 patients were treated in a neoadjuvant setting with sorafenib (400 mg orally twice daily). Five patients received treatment during 1 wk, and 5 patients received treatment during 4 wk. In both sorafenib-treated groups, baseline and posttreatment tumor targeting of (111)In-girentuximab were compared. Surgery was performed 3 d after the last image acquisition. Five additional patients were included as a control group and had only a single (111)In-girentuximab injection and scintigraphy without any treatment. Distribution of (111)In-girentuximab was determined scintigraphically ex vivo in a 1-cm lamella of the resected tumorous kidney. Expression of CAIX and of the vascular marker CD31 was determined immunohistochemically on specimens of both tumor and normal kidney tissue.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment with sorafenib resulted in a marked decrease of (111)In-girentuximab uptake in the tumor in clear cell RCC patients, especially in the group treated for 4 wk (mean change in both sorafenib-treated groups, -38.4%; range, +9.1% to -79.4%). Immunohistochemical analysis showed markedly reduced CD31 expression and vessel density in the sorafenib-treated groups but no differences in CAIX expression between the sorafenib-treated groups and the nontreated patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with sorafenib resulted in a treatment duration-dependent significantly decreased uptake of (111)In-girentumab in clear cell RCC lesions. These results indicate that the efficacy of antibody-mediated treatment or diagnosis modalities is hampered by TKI treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muselaers</LastName><ForeName>Constantijn H J</ForeName><Initials>CH</Initials><Affiliation>Radboud university medical center, Department of Urology, Nijmegen, The Netherlands.</Affiliation></Author><Author ValidYN="Y"><LastName>Stillebroer</LastName><ForeName>Alexander B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Desar</LastName><ForeName>Ingrid M E</ForeName><Initials>IM</Initials></Author><Author ValidYN="Y"><LastName>Boers-Sonderen</LastName><ForeName>Marye J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>van Herpen</LastName><ForeName>Carla M L</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>de Weijert</LastName><ForeName>Mirjam C A</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Langenhuijsen</LastName><ForeName>Johan F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Oosterwijk</LastName><ForeName>Egbert</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Leenders</LastName><ForeName>William P J</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Boerman</LastName><ForeName>Otto C</ForeName><Initials>OC</Initials></Author><Author ValidYN="Y"><LastName>Mulders</LastName><ForeName>Peter F A</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Oyen</LastName><ForeName>Wim J G</ForeName><Initials>WJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nucl Med</MedlineTA><NlmUniqueID>0217410</NlmUniqueID><ISSNLinking>0161-5505</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antigens, CD31</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>G250 monoclonal antibody</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Phenylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>sorafenib</NameOfSubstance></Chemical><Chemical><RegistryNumber>25X51I8RD4</RegistryNumber><NameOfSubstance>Niacinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance>Protein-Tyrosine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antigens, CD31</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Renal Cell</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Drug Synergism</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Intervention Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Kidney Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Niacinamide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Phenylurea Compounds</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CAIX</Keyword><Keyword MajorTopicYN="N">girentuximab</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">renal cell carcinoma</Keyword><Keyword MajorTopicYN="N">tyrosine kinase inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24396030</ArticleId><ArticleId IdType="pii">jnumed.113.131110</ArticleId><ArticleId IdType="doi">10.2967/jnumed.113.131110</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000016 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000016 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24396030
|texte= Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24396030" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |